Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression.

ABSTRACT:

Objective

The Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify, develop, and qualify biomarkers to support drug development in knee osteoarthritis (OA). The project's second phase, the PROGRESS OA study, aims to externally validate prognostic and response biomarkers identified in the earlier phase (phase 1). Here we present results assessing external validation of prognostic imaging biomarkers.

Design

PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for symptomatic knee OA. Radiographic progression was defined as joint space width loss (JSWL) ≥0.7 mm. Symptomatic progression was defined as increase of nine or more points in Western Ontario and McMaster Universities Arthri

SUBMITTER: Collins JE 

PROVIDER: S-EPMC12451203 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature